Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era

Agema, Willem R.P.; Monraats, Pascalle S.; Zwinderman, Aeilko H.; Winter, Robbert J. de; Tio, René A.; Doevendans, Pieter A.; Waltenberger, Johannes; Maat, Moniek P.M. de; Frants, Rune R.; Atsma, Douwe E.; Laarse, Arnoud van der; Wall, Ernst E. van der; Jukema, J. Wouter

doi:10.1016/j.ehj.2004.05.006

Cited by 59 publications

(64 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…141 These UK figures are therefore consistent with the rates from Liverpool quoted in our study. Evidence from other international studies shows comparable results in unselected patients in Canada (8.2%), 124 Switzerland (12.1% TVR with a more severe case mix) 82 and The Netherlands (9.6% TVR), 142 reinforcing confidence in the reliability of the CTC Liverpool data, where the combined elective/non-elective rate was 8.8%. In the USA, generally higher rates of repeat revascularisation are reported in registry studies: Ellis and colleagues 143 obtained an overall rate of 13.4% for patients treated between 1994 and 2001, with 54% of patients in risk subgroups with rates <10% and a further 33% with a risk of 12.1%; Wu and colleagues 144 used a cohort treated in 1999 including unstented PCI with an overall rate of 16.2%.…”

Section: Are the Ctc Data Reliable And Representative?supporting

confidence: 50%

“…Other recent studies, based on unselected patient data, have developed independent risk 142 found diabetes to be required unequivocally as an independent predictor in a multivariate analysis. Hence the CTC models are in no way discredited by the omission of specific variables conventionally presumed to be important.…”

Section: Why Do Identified Risk Factors Differ From Those Expected?mentioning

confidence: 99%

See 1 more Smart Citation

Drug-eluting stents: a systematic review and economic evaluation

Hill¹,

Boland²,

Dickson³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

Section: Are the Ctc Data Reliable And Representative?supporting

confidence: 50%

Section: Why Do Identified Risk Factors Differ From Those Expected?mentioning

confidence: 99%

Drug-eluting stents: a systematic review and economic evaluation

Hill¹,

Boland²,

Dickson³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Aegma et al reported a 10.3% target-vessel revascularization rate in a series of 3,146 patients followed for 9 months, 5 and Ellis et al reported an overall repeat revascularization rate of 13.4%. 6 In contrast, some randomized DES trials report BMS reintervention rates as high as 22.9%.…”

Section: Discussionmentioning

confidence: 99%

Bare-metal stent outcomes in an unselected patient population

Yock

Isbill²,

King

2006

Clin Cardiol

View full text Add to dashboard Cite

SummaryBackground: Randomized trials have shown that drug-eluting stents (DES) substantially reduce in-stent restenosis compared with bare-metal stents (BMS).Hypothesis: Revascularization event rates related to BMS restenosis may be higher in the trials setting than in real-world experience, calling into question the extent of benefit possible with widespread DES use in regular practice.Methods: Between December 1998 and March 2003, 17,102 patients with BMS registered in the Goodroe Healthcare Solutions Data Warehouse met the inclusion criteria for this retrospective study of catheterization laboratory data. We examined the database for evidence of diagnostic angiography or percutaneous coronary intervention (PCI) readmission within 1 year after stenting.Results: Repeat PCI was documented for 2,070 patients, and 232 were referred for coronary artery bypass graft surgery (CABG)-in sum, 13.5% of the cohort. Stented region revascularization was observed in 8.4%: 1,350 patients underwent subsequent PCI, and 84 of the patients referred for CABG had in-stent lesion recurrence. Only 1,207 (7.1%) patients required stent-related PCI after 30 days, the time frame consistent with restenosis.Conclusions: In this "real-world" series, reintervention of a stented region after the first follow-up month was documented in fewer than 8% of patients in a large cohort that had received BMS. The rate of clinical events potentially related to BMS instent restenosis in this large, unselected patient population is substantially lower than that in the control arms of some DES trials. The incremental benefit of widespread conversion from

show abstract

“…Processes involved in AVF patency, particularly vascular smooth muscle cell proliferation and inflammation, also play a key role in the development of coronary restenosis after percutaneous coronary intervention (13). In contrast with the scarcely available data on genetic determinants of AV access failure, the genetic background of coronary restenosis has been more established (12,13). Although our SNP selection covered a wide range of candidate genes in all involved mechanisms, the obtained results do not indicate an important role for our selected SNPs in the development of AVF failure.…”

Section: Discussionmentioning

confidence: 93%

“…Excessive accumulation of extracellular matrix is mediated by several growth factors (5,9,11). Morphologically, these stenotic lesions closely resemble restenotic lesions after percutaneous coronary intervention (12,13). Additional specific pathophysiologic stimuli for intimal hyperplasia in vascular access stenosis include the abnormal calcium/phosphate metabolism in patients with CKD that result in arterial as well as venous calcification of the tunica media (14).…”

Section: Introductionmentioning

confidence: 99%

Candidate Gene Analysis of Arteriovenous Fistula Failure in Hemodialysis Patients

Verschuren

Ocak²,

Dekker³

et al. 2013

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryBackground and objectives Arteriovenous fistula (AVF) failure remains an important cause of morbidity in hemodialysis patients. The exact underlying mechanisms responsible for AVF failure are unknown but processes like proliferation, inflammation, vascular remodeling, and thrombosis are thought to be involved. The current objective was to investigate the association between AVF failure and single nucleotide polymorphisms (SNPs) in genes related to these pathophysiologic processes in a large population of incident hemodialysis patients.Design, setting, participants, & measurements A total of 479 incident hemodialysis patients were included between January 1997 and April 2004. Follow-up lasted 2 years or until AVF failure, defined as surgery, percutaneous endovascular intervention, or abandonment of the vascular access. Forty-three SNPs in 26 genes, related to proliferation, inflammation, endothelial function, vascular remodeling, coagulation, and calcium/ phosphate metabolism, were genotyped. Relations were analyzed using Cox regression analysis.Results In total, 207 (43.2%) patients developed AVF failure. After adjustment, two SNPs were significantly associated with an increased risk of AVF failure. The hazard ratio (95% confidence interval) of LRP1 rs1466535 was 1.75 (1.15 to 2.66) and patients with factor V Leiden had a hazard ratio of 2.54 (1.41 to 4.56) to develop AVF failure. The other SNPs were not associated with AVF failure. ConclusionsIn this large cohort of hemodialysis patients, only 2 of the 43 candidate SNPs were associated with an increased risk of AVF failure. Whether other factors, like local hemodynamic circumstances, are more important or other SNPs play a role in AVF failure remains to be elucidated.

show abstract

Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era

Cited by 59 publications

References 18 publications

Drug-eluting stents: a systematic review and economic evaluation

Drug-eluting stents: a systematic review and economic evaluation

Bare-metal stent outcomes in an unselected patient population

Candidate Gene Analysis of Arteriovenous Fistula Failure in Hemodialysis Patients

Contact Info

Product

Resources

About